Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2026)

Camp4 Therapeutics has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $11.1 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $11.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $11.1 million (changed N/A YoY), and the FY2025 annual result was $9.4 million, up 2338.18% from the prior year.
• Current Deferred Revenue came in at $11.1 million for Q1 2026 at Camp4 Therapeutics, up from $9.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.1 million in Q1 2026 to a low of $385000.0 in Q4 2024.
• The 3-year median for Current Deferred Revenue is $5.2 million (2024), against an average of $5.5 million.
• Peak annual rise in Current Deferred Revenue reached 2338.18% in 2025, while the deepest fall reached 2338.18% in 2025.
• Camp4 Therapeutics' Current Deferred Revenue stood at $385000.0 in 2024, then surged by 2338.18% to $9.4 million in 2025, then advanced by 17.98% to $11.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $11.1 million (Q1 2026), $9.4 million (Q4 2025), and $385000.0 (Q4 2024), per Business Quant data.